Table 2. Meta-analysis of the association between XRCC1-Arg 399 Gln polymorphism and prostatic cancer risk.

	AG vs. AA				GG vs. AA				Recessive model				Dominant model
	OR(95%CI)	P	Phet	I2(%)	OR(95%CI)	P	Phet	I2(%)	OR(95%CI)	P	Phet	I2(%)	OR(95%CI)	P	Phet	I2(%)
Overall	0.95(0.83,1.09)	0.480	0.043	41.3	1.24(1.00,1.53)	0.047	0.048	40.4	1.20(1.06,1.36)	0.005	0.100	32.8	1.07(0.92,1.26)	0.373	0.001	59.2
Ethnicity
Asian	1.03(0.70,1.52)	0.873	0.061	59.3	1.55(1.02,2.35)	0.039	0.388	0.8	1.43(1.02,2.00)	0.038	0.383	1.9	1.13(0.81,1.58)	0.468	0.110	50.3
Caucasian	0.98(0.80,1.19)	0.817	0.062	49.9	1.06(0.79,1.42)	0.720	0.058	50.7	1.05(0.89,1.23)	0.567	0.146	37.1	1.10(0.85,1.44)	0.466	0.000	76.4
Africa	0.82(0.65,1.03)	0.086	0.480	0.0	1.48(1.09,2.01)	0.012	0.779	0.0	1.64(1.23,2.18)	0.001	0.934	0.0	0.97(0.79,1.19)	0.774	0.433	0.0
Source of control
PB	0.95(0.78,1.15)	0.576	0.040	49.0	1.38(0.99,1.91)	0.056	0.011	58.1	1.22(1.05,1.43)	0.012	0.016	55.7	1.05(0.87,1.26)	0.647	0.019	54.5
HB	0.95(0.76,1.20)	0.692	0.165	36.2	1.07(0.84,1.37)	0.585	0.622	0.0	1.16(0.93,1.44)	0.196	0.869	0.0	1.12(0.86,1.46)	0.409	0.035	58.4

PB: population-based; HB: hospital-based.